资讯

urologytimes3 天
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology. The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an ...
urologytimes3 天
FDA clears stapler for use with da Vinci SP surgical system
The SureForm 45 stapler is the first stapler cleared for single-port robotic surgery in the US, enhancing surgical control and efficiency. SmartFire technology in the stapler optimizes staple line ...
urologytimes5 天
An expert discusses patient counseling in wake of FDA’s labeling changes for testosterone
“It definitely makes it easier for providers [to counsel patients]," says Landon Trost, MD. With the FDA’s recent class-wide labeling changes for testosterone products 1, urologist Landon Trost, MD, ...
urologytimes5 天
Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
"“The approval of Gozellix is likely to both streamline and expand access to PSMA-PET imaging, hopefully broadening the distribution and use of gallium 68," says Kelly L. Stratton, MD, FACS. According ...
urologytimes5 天
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures
Kate H. Kraft, MD, MHPE, FACS, FAAP,Benjamin P. Saylor “I would say the take-home message for this study is that prescribing tamsulosin for a week prior to an anticipated surgery that involves ...
urologytimes5 天
Gene therapy shows encouraging efficacy for overactive bladder
URO-902 significantly improved daily micturitions and urgency episodes compared to placebo in women with OAB and UUI. The therapy showed a manageable safety profile, with treatment-emergent adverse ...
urologytimes6 天
Genetic test can predict risk of toxicity following radiation for prostate cancer
PROSTOX ultra test predicts late-grade GU toxicity in patients with prostate cancer postradiation, with an AUC of 0.762. The test's sensitivity and specificity were 0.576 and 0.948, respectively, in ...
urologytimes5 天
Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617
The study utilized 68Ga-PSMA-11 PET imaging to assess outcomes in prostate cancer patients treated with 177Lu-PSMA-617, focusing on whole-body SUVmean as a key parameter. Higher whole-body SUVmean ...
urologytimes6 天
What urologists can expect in Q2 of 2025
Gepotidacin, 177Lu-PSMA-617, and durvalumab received FDA approvals, marking significant advancements in urology treatment paradigms. UGN-102's NDA decision for LG-IR-NMIBC is expected by June 13, 2025 ...
urologytimes6 天
Resective Surgery and Minimally Invasive Procedures For BPH
A panelist discusses how benign prostatic hyperplasia (BPH) treatment has evolved to include a spectrum of minimally invasive and surgical interventions, ranging from emerging technologies like ...
urologytimes6 天
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
“To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” says Ekene Enemchukwu, MD, MPH, FACS, URPS. While ...
urologytimes10 天
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall ...